Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-27 21:44:55 - browse：923

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： 3 questions for the future of Biden's cancer moonshot

WSS

Hollywood unions extend contract negotiations for actors

Wildfire smoke exposes gaps in outdoor worker protections

Physician executives need more than on

3 questions for the future of Biden's cancer moonshot

What to expect at HLTH 2023, the health care industry conference

Supreme Court strikes down use of affirmative action

knowledge

Wikipedia

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Liquid biopsy for lung cancer is launched by Delfi

Hepatitis C has a cure — but many Americans still lack access to it

Hollywood unions extend contract negotiations for actors

As demand for Covid shots wanes, Moderna seeks its next success

FDA rejects Alnylam's heart disease treatment over insufficient data

Medicare proposal to cover medical devices draws a mixed reaction

The future of health care in the House

How to save PrEP access — and even expand it

Jerome Adams on the need for new antivirals for Covid

hotspot

Walensky prepares to leave CDC — and Congress — behind

Medicare proposal to cover medical devices draws a mixed reaction

Chemotherapy drug shortage eases slightly but still widespread

New air purifier tech could be key to improving indoor air quality

BioMarin wins approval for gene therapy to treat hemophilia A

Wildfire smoke exposes gaps in outdoor worker protections

knowledge

hotspot

focus

hotspot